Promoter holding
64.27%
IL
Indeus Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Indeus Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress s…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Indeus Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records66/100
Trust Score
Moderate
Indeus Life Sciences is assessed as Moderate with a Trust Score of 66/100. Indeus Life Sciences is an active private limited indian non-government company incorporated in 2007, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 27 Jun 2026 from the latest processed filings. Indeus Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
66/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
57/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 57/100 Moderate
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2023 - filings overdue.
- 1 auditor resignation(s) filed - latest: DELOITTE HASKINS & SELLS LLP on 2020-06-18.
- Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SHANTISUDHA DHARMARAJ SHETTY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SAMIR MADHUKAR GAIKWAD | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KANCHAN ATUL KULKARNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DHARMARAJ KARUNAKAR SHETTY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| FINNY JOSEPH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Genocare Pharma Private Limited
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 0 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Genocare Pharma Private Limited | Holding Company | 74.00% |
Key managerial personnel: DHARMARAJ KARUNAKAR SHETTY (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 45 · Distress 50
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Statutory filings appear overdue.
Compliance score is weak (57/100).
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 2.99 Lakh.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view52/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2023
Last AGM held
Annual general meeting
07 Apr 2023
Director appointed
SAMIR MADHUKAR GAIKWAD (Nominee Director)
31 Mar 2023
Latest balance sheet
Filed with ROC
03 Jan 2022
Director appointed
KANCHAN ATUL KULKARNI (Company Secretary)
22 Nov 2021
Director ceased
FINNY JOSEPH
29 Oct 2021
Securities allotted
847456 Equity Shares - 84.75 Lakh raised
21 Oct 2021
Securities allotted
2017799 Equity Shares - 2.38 cr raised
24 Sep 2021
Director appointed
FINNY JOSEPH (Director)
22 Feb 2021
Director appointed
SHANTISUDHA DHARMARAJ SHETTY (Director)
02 Oct 2020
Director ceased
Gagan Bhandar
27 Jun 2020
Director ceased
CORNELIS TER HAAR
01 Jun 2020
Director ceased
DHARMARAJ KARUNAKAR SHETTY
30 Mar 2020
Director appointed
DHARMARAJ KARUNAKAR SHETTY (Managing Director)
30 Sep 2019
Director ceased
KENNETH STOKHOLM
01 May 2019
Director ceased
HANS SCHRAM
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Harinder Medicare & Solutions Private Limited | U85110HR2012PTC047507 | Faridabad, Haryana, India |
| Pushpak Organics India Private Limited | U24240MH1985PTC035115 | Mumbai, Maharashtra, India |
| Lonand Gases Private Limited | U24111PN2011PTC141045 | Satara, Maharashtra, India |
| Tanul Laboratories (India) Private Limited | U24300MH2008PTC184862 | Kalyan, Maharashtra, India |
| Aushadhi Wellness Private Limited | U24239GJ2012PTC068468 | Rajkot, Gujarat, India |
| Shri Gopal Engineering And Chemical Works Private Limited | U24232UP1994PTC016623 | Uttar Pradesh, Uttar Pradesh, India |
| Dcs Agro Care Private Limited | U01111HR2018PTC123301 | Badshahpur, Haryana, India |
| Tripati Pesticide India Private Limited | U74900WB2015PTC206483 | Purba Medinipur, West Bengal, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Indeus Life Sciences before audits and certifications: compliance score 57/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Indeus Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Indeus Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 66/100, distress signals and MSME payment-delay disclosures - know whether Indeus Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Indeus Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Indeus Life Sciences an active company?
Indeus Life Sciences has MCA status “Active” with a compliance score of 57/100 (Moderate).
Is Indeus Life Sciences financially healthy?
Indeus Life Sciences has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.
Should I do business with Indeus Life Sciences?
Its overall Trust Score is 66/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Indeus Life Sciences?
The ultimate holding entity is Genocare Pharma Private Limited. 5 active director(s) are on record.
Does Indeus Life Sciences have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Indeus Life Sciences up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 57/100 (Moderate).
Is it risky to lend to Indeus Life Sciences?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
